VirnetX Holding Corporation — FY2022 Form 10-K
Business context and reporting period. This is the annual report for the fiscal year ended December 31, 2022, not a standalone fourth-quarter report. VirnetX develops and licenses patented internet-security technology, including its VirnetX One platform, War Room, Matrix, and GABRIEL products. Its business remains substantially dependent on patent licensing and litigation; the company reported approximately 205 patents and pending applications.
Financial performance and liquidity
| Metric | 2022 | 2021 | Context |
|---|---|---|---|
| Revenue | $48 thousand | $35 thousand | 2020 revenue was $302.6 million, largely from the Apple patent litigation award; 2022 revenue was not material. |
| Operating expenses | $22.1 million | $49.2 million | 2022 included $6.4 million R&D and $15.7 million SG&A. |
| Operating loss | $22.1 million | $49.2 million | With minimal revenue, operating margins are not informative. |
| Net loss | $36.3 million | $42.9 million | Loss per share was $0.51 in 2022 versus $0.60 in 2021. |
| Operating cash flow | $(16.9) million | $(51.7) million | Net cash declined by $55.5 million in 2022. |
| Cash and cash equivalents | $86.6 million | $142.0 million | |
| Short-term investments | $65.5 million | $27.3 million | Cash plus investments totaled about $152.0 million at year-end 2022. |
| Total liabilities | $0.7 million | $1.1 million | No debt balance is reported in the supplied financial statements. |
All figures above are in U.S. dollars; financial statement amounts are in thousands unless indicated otherwise. The company said its cash and investments were sufficient to fund its current level of costs and working capital for the foreseeable future. A $16.0 million income tax provision contributed to the 2022 net loss; VirnetX recorded a full valuation allowance against its $18.6 million of deferred tax assets.
Material changes versus the prior comparable period
- Revenue rose slightly from $35 thousand to $48 thousand but remained negligible relative to operating costs.
- SG&A fell to $15.7 million from $52.7 million, primarily as patent-litigation legal fees decreased to $3.3 million from $41.8 million. R&D increased to $6.4 million from $5.6 million.
- Operating cash outflow narrowed to $16.9 million from $51.7 million, while cash and cash equivalents fell by $55.5 million. Purchases of investments were a major investing cash outflow.
- The 2021 balance sheet included a $16.0 million net deferred tax asset; the 2022 balance sheet reported none after a full valuation allowance.
- VirnetX restated previously issued 2021 financial statements because of an overstatement of deferred tax assets and identified a material weakness in internal control over financial reporting. Management says it remediated the weakness and concluded controls were effective at December 31, 2022.
Outlook, litigation, and key risks
- No quantified financial guidance. Management expects to pursue product sales and licensing, and stated that discussions with prospective partners took place in late 2022 and early 2023. The filing gives no clear revenue or earnings forecast and cautions that significant product revenue is uncertain.
- War Room and VirnetX Matrix launched in the United States in 2022; the company expected to pursue launches in Asia-Pacific and Europe during 2023. Management described the products’ target markets as growing, but adoption, sales cycles, and conversion of discussions into contracts remain uncertain.
- Apple II litigation is a major contingency. After year-end, on March 31, 2023, the Federal Circuit vacated the district court judgment and remanded with instructions to dismiss the case as moot. VirnetX said it was evaluating possible rehearing or Supreme Court review. The filing recognizes litigation-related gains only when cash is collected; no Apple II proceeds are included in 2022 results.
- On March 30, 2023, the Federal Circuit also affirmed PTAB findings that certain claims of two patents asserted in related proceedings were unpatentable. Further appeals and patent challenges remain, creating uncertainty around the value and enforceability of the portfolio.
- On March 30, 2023, the board declared a special cash dividend of $1.00 per share, payable on or about April 17, 2023. The company also said it intends to distribute a substantial portion of any net proceeds from the final Apple II outcome, if proceeds are received.
- Principal risks include patent validity and litigation outcomes, dependence on a limited number of licensing sources, low product commercialization to date, cash use, privacy and cybersecurity regulation, long sales cycles, and possible dilution. The company also disclosed related-party aircraft-service payments of approximately $1.1 million in 2022 to an entity controlled by its CEO and chief administrative officer.
Most important facts for investors to verify
- Latest status and potential remedies in Apple II, and the financial effect of the March 2023 Federal Circuit decisions and other patent challenges.
- Whether product discussions and planned international launches result in signed contracts, recurring revenue, and customer adoption.
- Cash and investment balances, investment values and maturities, and the rate of operating cash consumption.
- The effects of the full deferred-tax valuation allowance and whether the prior financial-statement restatement and control remediation have any further consequences.
- Payment and record dates for the March 2023 special dividend, and the conditions governing any future litigation-related distribution.